Literature DB >> 23108791

Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats.

Yogendra Singh1, Kulwinder Singh, P L Sharma.   

Abstract

To investigate the combined effect of aliskiren, a renin inhibitor, and AVE 0991, a Mas-receptor agonist, in experimental hypertension (HT) in rats. HT was produced by administration of deoxycorticosterone acetate (DOCA) and mean arterial blood pressure (MABP) was assessed by tail-cuff method. Treatments were started from 4th week onwards and were continued for 9 days. A significant increase in MABP was noted after 1 week in DOCA control rats, as compared with the base line value. A stable HT developed after 4 weeks of DOCA administration. Treatments with aliskiren and AVE 0991 alone, dose-dependently decreased MABP in DOCA-treated rats. Further, combination of low doses of aliskiren and AVE 0991 significantly reduced MABP, as compared with DOCA control rats and with either drug alone in low doses. It may be concluded that treatment with aliskiren produced down-regulation of both harmful Ang II-AT1-receptor and survival Ang(1-7)/Mas-receptor axis of RAAS. Treatment with combination of low doses of aliskiren and AVE 0991, for the first time, has been shown to produce synergistic blood pressure lowering effect. Therefore, combination of renin inhibitor with Mas-receptor agonist may prove beneficial for the treatment of hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108791     DOI: 10.1007/s11010-012-1489-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  41 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice.

Authors:  Virginia S Lemos; Denise M R Silva; Thomas Walther; Natalia Alenina; Michael Bader; Robson A S Santos
Journal:  J Cardiovasc Pharmacol       Date:  2005-09       Impact factor: 3.105

Review 3.  Antihypertensive effects of angiotensin-(1-7).

Authors:  M C Chappell; S N Iyer; D I Diz; C M Ferrario
Journal:  Braz J Med Biol Res       Date:  1998-09       Impact factor: 2.590

4.  Stimulation of basolateral Na(+)-HCO3- cotransporter by angiotensin II in rabbit renal cortex.

Authors:  S Eiam-Ong; S A Hilden; C A Johns; N E Madias
Journal:  Am J Physiol       Date:  1993-08

5.  Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney.

Authors:  T Wang; G Giebisch
Journal:  Am J Physiol       Date:  1996-07

6.  Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy.

Authors:  Kulwinder Singh; Tajinder Singh; P L Sharma
Journal:  Ther Adv Cardiovasc Dis       Date:  2011-05-09

Review 7.  Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Authors:  Z H Israili
Journal:  J Hum Hypertens       Date:  2000-04       Impact factor: 3.012

8.  Angiotensin (1-7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats.

Authors:  Jennifer C Sullivan; Kanchan Bhatia; Tatsuo Yamamoto; Ahmed A Elmarakby
Journal:  Hypertension       Date:  2010-08-16       Impact factor: 10.190

9.  Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.

Authors:  Alice Stanton; Chris Jensen; Juerg Nussberger; Eoin O'Brien
Journal:  Hypertension       Date:  2003-11-03       Impact factor: 10.190

10.  Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.

Authors:  Bernhard Pilz; Erdenechimeg Shagdarsuren; Maren Wellner; Anette Fiebeler; Ralf Dechend; Petra Gratze; Silke Meiners; David L Feldman; Randy L Webb; Ingrid M Garrelds; A H Jan Danser; Friedrich C Luft; Dominik N Müller
Journal:  Hypertension       Date:  2005-08-15       Impact factor: 10.190

View more
  13 in total

Review 1.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

Review 2.  Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.

Authors:  Rodrigo Araujo Fraga-Silva; Anderson Jose Ferreira; Robson Augusto Souza Dos Santos
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

3.  Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!

Authors:  Vajir Malek; Sachin V Suryavanshi; Nisha Sharma; Yogesh A Kulkarni; Shrikant R Mulay; Anil Bhanudas Gaikwad
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 4.  New Molecules for Treating Resistant Hypertension: a Clinical Perspective.

Authors:  Omar Azzam; Marcio G Kiuchi; Jan K Ho; Vance B Matthews; Leslie Marisol Lugo Gavidia; Janis M Nolde; Revathy Carnagarin; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2019-09-10       Impact factor: 5.369

Review 5.  Brain angiotensin converting enzyme-2 in central cardiovascular regulation.

Authors:  Mazher Mohammed; Clara Berdasco; Eric Lazartigues
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.124

Review 6.  New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?

Authors:  Ludovit Paulis; Romana Rajkovicova; Fedor Simko
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

7.  COVID-19 transmission through host cell directed network of GPCR.

Authors:  Yogendra Singh; Gaurav Gupta; Saurabh Satija; Kavita Pabreja; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Drug Dev Res       Date:  2020-04-23       Impact factor: 4.360

Review 8.  Antifibrotic Roles of RAAS Blockers: Update.

Authors:  Ying-Ying Zhang; Ying Yu; Chen Yu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Sustained elevation of NF-κB activity sensitizes offspring of maternal inflammation to hypertension via impairing PGC-1α recovery.

Authors:  Yafei Deng; Qi Zhang; Hongqin Luo; Xianhua Chen; Qi Han; Fangjie Wang; Pei Huang; Wenjing Lai; Xiao Guan; Xiaodong Pan; Yan Ji; Wei Guo; Ling Che; Yuan Tang; Liangqi Gu; Jianhua Yu; Michael Namaka; Youcai Deng; Xiaohui Li
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379

Review 10.  Novel Medical Treatments for Hypertension and Related Comorbidities.

Authors:  Jared Davis; Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2018-08-25       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.